The retina works a little like a camera sensor built from two different pixel types: rods that pick up faint light and cones that handle colour and daylight detail. Retinitis Pigmentosa is what happens when the rod pixels begin failing first, in a pattern that is broadly predictable across patients even though the speed of change is not. It remains the leading inherited driver of gradual vision loss worldwide, and that is precisely why the term keeps resurfacing once an ophthalmologist in Uganda first mentions it to a family.
No two RP patients travel the same road at the same pace, so before any treatment discussion begins, we need a clear read on exactly how much ground has already been covered. That single data point — the current stage of disease — tends to steer nearly every recommendation that comes afterward.
TRP is not caused by one faulty gene but by well over 80 of them, with RHO, USH2A, and RPGR turning up most frequently. The specific gene involved decides how the condition moves through a bloodline — dominant in some families, recessive in others, and X-linked in a third pattern altogether. Where a Ugandan household has multiple affected members, mapping that inheritance pattern across the family often reveals nearly as much as the eye examination itself.
Four investigations carry most of the diagnostic weight: full-field electroretinography, which records the electrical signal generated by rods and cones; OCT scanning, which images the surviving photoreceptor layers; Goldmann visual field testing, which maps precisely how far peripheral vision has retreated; and fundus autofluorescence, which outlines the border between healthy and degenerating retina. Genetic testing is offered whenever feasible, since the particular gene involved can reshape both the outlook and the treatment options worth pursuing.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Where a patient’s assessment supports it, regenerative stem cell therapy forms one piece of a broader plan built around preserving remaining retinal function. That plan typically runs alongside low-vision rehabilitation, guidance on safer lighting and mobility, and nutritional advice — so a patient travelling from Uganda leaves with an ongoing management strategy rather than a single isolated procedure.
“Not necessarily — outcomes differ substantially from person to person, largely depending on which gene is responsible and how it is inherited. Many people with RP keep meaningful, usable vision, especially centrally, well into later life. That variability is exactly why every case is assessed individually rather than assumed to follow one fixed path.”
”
That depends on the inheritance pattern tied to the specific gene at fault, and genetic testing is the most dependable way to work that out. We can talk you through what that likely means for your family, though for decisions around future children we would recommend involving a certified genetic counsellor as well.”
“A routine eye check is built to catch things like refractive error or cataract, not RP. Confirming and staging RP calls for equipment — ERG and detailed field mapping in particular — that most general clinics don’t stock, which is why a focused evaluation usually means travelling somewhere it is available.”
“Bring along any existing eye reports, a general sense of your family’s eye-health history, and a rough timeline of when symptoms began and how they have shifted since. Even that basic background can speed up the diagnostic process considerably.”
